Watchman or Warfarin? Choosing a Method of Stroke Prevention

Could a tiny device designed to avert stroke-provoking clots be a substitute for medication? The technology is an option for certain at-risk patients.

8:00 AM

Author | Jane Racey Gleeson

For certain non-valvular atrial fibrillation patients who do not respond well to (or are at risk from) taking warfarin, a lightweight heart implant the size of a quarter has been hailed as a feasible alternative.

In recent trials, researchers found a clot-stopping device known as the Watchman was comparable to warfarin in offering effective protection from disabling stroke, hemorrhagic stroke and cardiovascular death.

"This is certainly something that can and should be considered," says Hakan Oral, M.D., a cardiologist at the University of Michigan Frankel Cardiovascular Center — one of the first facilities in the nation to use the pioneering device. But it's not right for everyone.

How the Watchman works

The Watchman is inserted with a wide-sheathed catheter placed through an incision in the patient's upper leg. Once in place, the self-expanding device is opened (similar to an umbrella) to seal off the heart's left atrial appendage, where harmful blood clots can form and then enter the bloodstream, thus reducing the risk of stroke and other systemic embolization.

The device bears a surface covered with a thin, permeable filter, allowing blood to pass through while simultaneously stopping clots. A patient's own heart tissue will grow over the permanent implant in time.

The Watchman comes in several sizes (as large as 33 millimeters) to accommodate individual left atrial appendages.

Who is a candidate?

A team of specialists determines whether patients are eligible for the device.

According to the Food and Drug Administration (PDF), the Watchman is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:

  • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy;

  • Are deemed by their physician(s) to be suitable for warfarin; and

  • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared with warfarin.

Despite the Watchman's inconspicuous size and relative ease of insertion with general anesthesia and, typically, one night of recovery in the hospital, it isn't appropriate for everyone.

For example, those who can take warfarin without incident or risk, Oral says, need a compelling reason to receive the implant.

"If a patient has a high risk of bleeding while on blood thinners, then it is a very good option," he notes, adding that general risks of taking such medication increases with age. In turn, that makes certain older patients suitable candidates.

Weaning off warfarin

Although one of the goals of implanting the Watchman is to help wean an individual off warfarin, the drug will remain a part of the patient's regimen for 45 days after the Watchman is inserted. After that, clinicians will use a transesophageal echocardiogram to determine if the implant has successfully closed the opening of the left atrial appendage.

"If all goes well, the patient is taken off of warfarin and put on a different type of blood thinner known as Plavix, along with aspirin, for another four and one-half months," says Oral. 

At that point, the patient stops taking Plavix and continues with an aspirin regimen. The Watchman, then, will keep watch on its own.


More Articles About: Health Tech Atrial Fibrillation Repair Cardiovascular: Treatment & Surgery
Health Lab word mark overlaying blue cells
Health Lab

This article is from the Health Lab digital publication.

Media Contact Public Relations

Department of Communication at Michigan Medicine

MichMedmedia@med.umich.edu

734-764-2220

Newsletter

Get a weekly digest of medical research and innovation, straight to your inbox.

Subscribe
Featured News & Stories tavr stroke blue cardiovascular red inside blue background
Health Lab
Hospitals without highest stroke care designation may miss them after heart procedure
Using stroke as a measure of quality after TAVR could put stroke centers at a disadvantage, the study suggests
scientist examining a kidney
Health Lab
An AI model predicting acute kidney injury works, but not without some tweaking
The model identified AKI 48 hours in advance, allowing ample time for clinicians to intervene and provide treatment.
machine green laser grid metal
Health Lab
Tracking radiation treatment in real time promises safer, more effective cancer therapy
Radiation, used to treat half of all cancer patients, can be measured during treatment for the first time with precise 3D imaging developed at the University of Michigan.
Vein-Red-Blood-Cells-Plaque.jpg
Health Lab
Massive international study uncovers genes involved in heart disease
Scientists link dozens of new genome sites to coronary artery disease risk and pioneer a powerful method for illuminating the biological roots of common disease.
Child on device with parent in kitchen
Health Lab
Frequently using digital devices to soothe young children may backfire
Smartphones and tablets may help calm down a preschooler short term but could reduce opportunities to practice emotional coping skills, a study suggests.
woman smiling hospital bed UM pillow
Health Lab
Her heart stopped more than 25 times. ECMO saved her life.
After two birthdays in the hospital, she celebrated with a brand-new heart.